French biopharmaceutical firm Ipsen posted robust first-half financials, reporting revenue of EUR 2.19 billion, an increase of 20.4% compared with the year-earlier period. The top-line figure outperformed the consensus estimate of EUR 1.56 billion provided by two analysts.
On an operating basis, Ipsen recorded adjusted EBIT of EUR 844.90 million for the first half, above a EUR 721 million estimate from one analyst and representing a 28.8% rise from the prior-year period. The company said its core operating margin widened by 2.5 percentage points to reach 38.6%.
Management attributed the sales expansion to its portfolio beyond Somatuline, noting that all three of the company’s therapeutic areas contributed to revenue growth.
On a per-share basis, Ipsen reported adjusted earnings of EUR 7.33 for the first half, while reported earnings per share stood at EUR 4.86. Reported EBIT for the period was EUR 564.80 million, translating to an EBIT margin of 25.8%.
Following the strong first-half performance, Ipsen raised its full-year guidance for 2026. The company now expects total sales growth above 20% at constant exchange rates, an upward revision from its prior forecast. It also lifted the outlook for its core operating margin to above 37% of total sales.
Ipsen highlighted a modest currency headwind in its guidance, saying it anticipates roughly a 1% adverse impact on 2026 total sales based on June exchange rates.
The company cited positive Phase III trial results for two programs - Dysport in migraine treatment and Iqirvo in primary biliary cholangitis - as supporting its growth trajectory. In addition, Ipsen noted that recent and proposed acquisitions of Memo Therapeutics AG and Kartos Therapeutics have added late-stage assets to its development pipeline.
Key financial metrics
- First-half revenue: EUR 2.19 billion (+20.4% year-on-year)
- Adjusted EBIT: EUR 844.90 million (+28.8% year-on-year)
- Core operating margin: 38.6% (up 2.5 percentage points)
- Adjusted EPS: EUR 7.33; Reported EPS: EUR 4.86
- Reported EBIT: EUR 564.80 million; EBIT margin: 25.8%
The company’s revised full-year guidance and margin targets reflect the stronger-than-anticipated first-half results and the addition of late-stage candidates to its pipeline. Observers will be watching how the currency environment and integration of acquired assets affect execution for the remainder of 2026.